Community Health Media

Can earlier ESR1 mutation detection help delay progression and preserve quality of life? In this episode of CHM Conversations, Dr. Hope Rugo and Dr. Rebecca Shatsky discuss the evolving role of oral SERDs and ctDNA monitoring in HR+ mBC. The conversation centers on the SERENA-6 trial and the strategy of identifying ESR1 mutations before radiographic progression. Dr. Rugo and Dr. Shatsky explore ho...

How are clinicians navigating the complex balance between immunotherapy and antibody-drug conjugates? In this episode of CHM Conversations, Dr. Neil Iyengar and Dr. Ticiana Leal discuss the integration of Dato-DXd into the rapidly evolving treatment paradigms for breast and lung cancer. The experts break down the practicalities of sequencing these therapies, moving beyond traditional chemotherapy...

Can molecular monitoring help clinicians intervene earlier to extend the benefit of first-line therapy? In this episode of CHM Conversations, Dr. Neil Iyengar, Dr. Manali Bhave, and Dr. Reshma Mahtani discuss overcoming resistance in HR+ mBC. The conversation focuses on the SERENA-6 trial and the strategy of using serial ctDNA monitoring to catch ESR1 mutations before radiographic progression. Dr....

Are we moving past the traditional "wait for progression" model in HR+ mBC? In this episode of CHM Conversations, Dr. Megan Kruse and Dr. Carol Tweed examine how molecular resistance monitoring is redefining the treatment timeline. The discussion highlights the shift toward a proactive approach, focusing on the clinical utility of serial ctDNA testing as seen in the SERENA-6 trial. Dr. K...

What if we could change treatment before scans show progression? In this episode of CHM Conversations, Dr. Jason Mouabbi and Dr. Ahmed Elkhanany explore the impact of ESR1 mutations and the clinical shift toward "molecular progression" in HR+ mBC. The discussion breaks down the SERENA-6 trial and how early ctDNA detection may allow clinicians to switch therapy before radiologic progressi...

How are clinicians navigating the growing number of targeted therapy options in HR-positive, HER2-negative metastatic breast cancer? In this CHM Conversations episode, Drs. Rebecca Shatsky and Reva Basho discuss the critical role of genomic profiling—specifically PIK3CA, AKT, PTEN, and ESR1—in guiding second-line treatment for HR+/HER2- metastatic breast cancer. The panel compares the clinical use...

How are clinicians optimizing the use of AKT inhibitors in HR-positive metastatic breast cancer? In this CHM Conversations episode, Drs. Neil Iyengar, Manali Bhave, and Reshma Mahtani explore the shifting second-line landscape for HR+/HER2- metastatic breast cancer. The discussion centers on the clinical integration of capivasertib and the necessity of biomarker testing—specifically PIK3CA, AKT, P...

How is molecular profiling reshaping HR+ metastatic breast cancer treatment? In this episode of CHM Conversations, Dr. Erica Mayer and Dr. Seth Wander navigate the evolving landscape of endocrine resistance and the PI3K/AKT pathway. They discuss the shifting roles of ESR1 and PIK3CA mutations, the rise of ctDNA in clinical sequencing, and the practicalities of integrating newer therapies like capi...

Can early intervention change the course of metastatic HR+ breast cancer? In this expert discussion, Dr. Seth Wander and Dr. Erica Mayer break down the practice-changing SERENA-6 trial and the emerging role of camizestrant in ESR1-mutated metastatic breast cancer. From ctDNA monitoring and early resistance detection, to quality-of-life improvements and precision endocrine therapy—they explore how...

In this special Spanish-language episode, experts Dr. Ricardo Alvarez, Dr. Marcela Mazo-Canola, and Dr. Ana Sandoval-Leon sit down to discuss the breakthroughs transforming modern breast oncology. The panel explores how personalized medicine is redefining outcomes and quality of life across the spectrum of HER2-positive, triple-negative, and hormone receptor-positive breast cancers. From the integ...

What happens when breast and thoracic oncology collide over the future of ADCs? In this cross-specialty conversation, Dr. Jason Mouabbi and Dr. Eric Singhi explore how antibody-drug conjugates are reshaping both breast and lung cancer treatment. From T-DXd and datopotamab deruxtecan to HER2-low disease, EGFR-mutated NSCLC, ILD management, sequencing strategies, and the future of combination ADC th...

What if we could detect endocrine resistance before it shows up on scans? In this CHM Conversations episode, Dr. Sigrun Hallmeyer and Dr. William Gradishar break down the SERENA-6 trial and what it means for the future of HR-positive, HER2-negative metastatic breast cancer. From early detection of ESR1 mutations using ctDNA to switching therapy before clinical progression, this discussion explores...

The HER2-positive landscape is undergoing its most significant shift in over a decade! In this in-depth CHM Conversations episode, VK Gadi and Tarah Ballinger break down the practice-changing data behind DB09, PATINA, HER2CLIMB-05, DB05, and DB11 — and what these trials mean for real-world patient care. This deep dive explores the critical transition from traditional maintenance habits to optimize...

In this expert discussion, Dr. VK Gadi and Dr. Ruta Rao break down the data that’s reshaping treatment for HER2-positive breast cancer — from DESTINY-Breast 05 and 11 to the first-line metastatic implications of DESTINY-Breast 09. They explore what the numbers really mean for patients with residual disease, how CNS risk and toxicity factor into decision-making, and where T-DXd may (or may not) rep...

Recorded live, this in-depth conversation features Dr. Irene Kang and Dr. Aditya Bardia breaking down the DESTINY-Breast09 data and what it means for first-line treatment of metastatic HER2-positive breast cancer. From challenging the long-standing THP standard to unpacking unprecedented progression-free survival, higher complete response rates, and CNS activity with T-DXd, this discussion explore...

Recorded with Drs. Neil Iyengar and Komal Jhaveri, this in-depth discussion breaks down the most practice-shifting data in early-stage HER2-positive breast cancer — from neoadjuvant to adjuvant decision-making. The conversation explores DESTINY-Breast11 and its unprecedented pathologic complete response rates with sequential T-DXd followed by THP, including an 83% pCR in hormone receptor–negative...

Recorded live with Drs. Gregory Vidal and Nusayba Bagegni, this in-depth conversation tackles one of the most provocative questions in HER2-positive metastatic breast cancer today: are we finally approaching cure? The discussion spans more than a decade of progress — from the CLEOPATRA regimen and its long tail of durable responders to the practice-changing data from DESTINY-Breast09 showing a 40-...

Recorded live, this in-depth conversation features Dr. Alison Conlin and Dr. Heather McArthur as they break down the evolving role of antibody–drug conjugates in early-stage HER2-positive breast cancer. The discussion dives into DESTINY-Breast 11 and DESTINY-Breast 05, exploring how trastuzumab deruxtecan is challenging long-standing neoadjuvant and adjuvant paradigms. From pathologic complete res...

For more than a decade, the Cleopatra regimen transformed outcomes in HER2-positive metastatic breast cancer — delivering landmark overall survival gains and redefining long-term disease control. Recorded at SABCS, this expert roundtable features Dr. Bill Gradishar, Dr. Tarah Ballinger, and Dr. Megan Kruse as they examine how the HER2 landscape is evolving in the era of antibody–drug conjugates. T...

Recorded live around the latest data from SABCS, ASCO, and ESMO, this in-depth conversation features Dr. Mark Pegram and Dr. Carol Tweed examining whether the long-standing Cleopatra regimen is finally giving way to a new first-line standard in HER2-positive metastatic breast cancer. From Destiny-Breast09 and unprecedented progression-free survival results to response depth, CNS considerations, an...

For more than a decade, CLEOPATRA defined first-line therapy in HER2-positive metastatic breast cancer. Now, DESTINY-Breast09 is forcing a fundamental rethink. In this in-depth roundtable, Drs. Neil Iyengar, Komal Jhaveri, and Igor Makhlin examine: • The legacy — and limitations — of CLEOPATRA • DESTINY-Breast09’s unprecedented ~40-month PFS • When T-DXd + pertuzumab should move to the frontline •...

Recorded at SABCS 2025, Dr. Neil Iyengar and Dr. Martin Dietrich break down the data that may finally dethrone CLEOPATRA as the long-standing first-line standard for HER2-positive metastatic breast cancer. From the historic success of dual HER2 inhibition to the game-changing DESTINY-Breast09 results showing median PFS exceeding 40 months, this conversation explores what true progress looks like —...

Recorded live at ASCO 2025, Amy Krie, Mabel Mardones, and Anne O'Dea break down the data that could redefine first-line treatment for HER2-positive metastatic breast cancer. From the legacy of CLEOPATRA to the stunning DB09 results showing median PFS exceeding 40 months, this expert roundtable explores what this shift means in real-world practice. They tackle patient selection, CNS metastases, tox...

Recorded at the 2025 San Antonio Breast Cancer Symposium, Dr. Mark Pegram (Stanford University) and Dr. Fengting Yan (Swedish Cancer Institute) break down the data that may redefine first-line treatment for HER2-positive metastatic breast cancer. This expert discussion dives deep into DESTINY-Breast09, exploring unprecedented progression-free survival results with T-DXd + pertuzumab, implications...

In this deep-dive conversation, Dr. Bill Gradishar and Dr. Tiffany Traina break down two pivotal first-line trials reshaping treatment for metastatic triple-negative breast cancer. They explore TROPION-Breast02 and ASCENT-03, unpacking progression-free survival, overall survival, response rates, toxicity profiles, and what truly differentiates datopotamab deruxtecan from sacituzumab govitecan in r...